IDH2 and central nervous system cancer: The G-CIMP-low subtype accounts for approximately 6% of all IDH-mutant gliomas and is characterized by lower levels of DNA methylation at specific sites and is associated with an unfavorable outcome compared to the G-CIMP-high subtype, accounting for approximately 55% of all IDH-mutant diffuse primary gliomas and 1p16q codeleted subtype accounting for approximately 39% of all IDH-mutant diffuse gliomas [106].